LimFlow

LimFlow is a major European VC success story – a French medtech company created and incubated by the visionary team of entrepreneurs that pioneered Sofinnova Partners’ medtech accelerator, MD Start. The company graduated from incubation and was then backed by Sofinnova’s growth-stage fund, Sofinnova Crossover 1, as the fund’s inaugural deal.

The company announced on 1 November 2023, that it was set to be acquired by Inari Medical for as much as $415 million, including $250 million upfront.

LimFlow’s game-changing technology, which has received FDA approval, is a life-saving option for patients who face amputation because of Critical Limb Ischemia (CLI). CLI is the most severe form of peripheral artery disease and often occurs in patients suffering from coronary artery disease, diabetes, obesity, high cholesterol, and high blood pressure. Patients with CLI experience profound, chronic pain and if untreated can develop festering wounds or infections that lead to major limb amputation, an event closely associated with increased mortality and reduced quality of life.

LimFlow enables clinicians to bring new hope to end-stage CLI patients when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve pain, promote wound healing, reduce amputations, and restore mobility, giving patients the possibility of living a normal life.